Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mayne’s Generics Segment Sees Double-Digit Drop In Sales

Company Expects NuvaRing Generic And Pipeline Products To Drive Growth

Executive Summary

Despite a double-digit drop in sales of generics business for the financial year ending 30 June 2020, South Australia-based Mayne filed for three generics with the US FDA and a “potential launch of generic NuvaRing.”

You may also be interested in...



Mayne Knocked Back Again On US NuvaRing Rival

Mayne Pharma has received a further setback in its attempt to bring a generic version of NuvaRing to the US market after the FDA issued the firm with another complete response letter.

Generics Industry Counts Cost Of Stormy Second Quarter

As the global generics industry had predicted, the unexpected growth seen in the first quarter of 2020 due to forward buying caused by COVID-19 levelled off in the second quarter. However, a few companies managed to report a “mixed” second quarter or a positive first half for 2020, even after experiencing challenges, such as operational interruptions, posed by the pandemic.

Mayne Reduces Resources For Generics Business

Tough operating conditions in the US retail generics markets have led Mayne Pharma to cut resources allocated to generics as it narrows its focus onto dermatology and women’s health.

Topics

UsernamePublicRestriction

Register

LL1131980

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel